KLHL12 Inhibitors

Chemical inhibitors of KLHL12 function through various mechanisms to impede its activity within the cell. Proteasome inhibitors such as Velcade, MG-132, Epoxomicin, Lactacystin, MLN2238, Carfilzomib, Oprozomib, Delanzomib, Marizomib, and ONX 0914 operate on a similar principle. These inhibitors prevent the proteasomal degradation of proteins that are normally ubiquitinated by KLHL12. The accumulation of these substrates within the cell can result in sequestration of KLHL12, as it becomes engaged with these undegraded proteins, thereby inhibiting its ability to ubiquitinate additional substrates. This indirect method of inhibition relies on the concept that the buildup of KLHL12's substrates can lead to a functional bottleneck, where the protein is unable to carry out its normal biological role in tagging proteins for degradation because it is occupied with an excess of previously ubiquitinated proteins that are not being cleared by the proteasome. Other inhibitors affect the ubiquitination process more upstream. For example, Pyr-41 targets the ubiquitin-activating enzyme E1, a pivotal enzyme in the ubiquitination cascade. By inhibiting this enzyme, Pyr-41 effectively blocks the ubiquitination process at its initial step, preventing the activation of ubiquitin itself. This action means that KLHL12 cannot fulfill its role in transferring ubiquitin to substrates because the ubiquitin is not activated for conjugation. Auranofin, though not a direct inhibitor of the ubiquitination pathway, can alter the redox environment within the cell. Since protein function, including the ubiquitination process, can be sensitive to redox states, the modulation of this environment by Auranofin can lead to an indirect inhibition of KLHL12's activity. The change in redox state may affect the stability and interaction of proteins, including those involved with KLHL12's pathway, thus interfering with KLHL12's ability to ubiquitinate its substrates effectively.